NAXGLIM-M1

Overview

NAXGLIM-M1 is specifically formulated for newly diagnosed obese diabetic patients who require effective dual-mechanism glycaemic control from the outset. Each tablet combines Glimepiride 1mg (a third-generation sulfonylurea) with Metformin Hydrochloride 500mg in a sustained-release matrix.

The combination addresses two core defects in Type 2 Diabetes simultaneously — insufficient insulin secretion and peripheral insulin resistance — making it particularly well-suited for obese patients who commonly present with both pathologies at diagnosis.

Indications

• Newly diagnosed obese patients with Type 2 Diabetes Mellitus
• Patients requiring dual oral antidiabetic therapy from initiation
• Co-morbid diabetic patients with hypertension, hyperlipidaemia, or cardiac disease
• Type 2 DM patients where monotherapy has not achieved glycaemic targets

Key Benefits

Dosage & Administration

• Standard dose: 1 tablet once or twice daily with meals
• Titration: Initiate with once-daily dosing; increase frequency after 4–8 weeks if HbA1c target not achieved
• Must be taken with food to minimise hypoglycaemia risk (glimepiride) and GI effects (metformin)
• Swallow whole — SR matrix must not be crushed or split
• Monitor renal function (eGFR) at least annually; withhold if eGFR < 30

Contraindications

• Type 1 diabetes mellitus or diabetic ketoacidosis
• eGFR < 30 mL/min/1.73m² (severe renal impairment)
• Hypersensitivity to glimepiride, sulfonamides, metformin, or any excipient
• Acute or chronic hepatic impairment (lactic acidosis risk)
• Acute conditions with risk of renal deterioration (severe infection, dehydration, surgery)
• Pregnancy and lactation
• Iodinated contrast administration — temporarily discontinue 48 hours prior